

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (currently amended): A method for treating beta-thalassaemia, comprising
administering to a subject in need of treatment an effective amount Use of angelicin or a structural
analogue thereof for the preparation of a medicament for the therapeutic treatment of beta-
thalassaemia.

Claim 2. (currently amended): The method Use according to claim 1, wherein the
structural analogue is selected from the group consisting of linear and angular coumarins, optionally
substituted, heteroanalogues of angelicin, thiopyrano-benzofurans, acylangelicins, alkylangelicins,
alkoxycarbamoyangelicins, psoralens, and isopsoralens, optionally substituted.

Claim 3. (currently amended): The method Use according to claim 2, wherein the
structural analogue is bergapten.

Claim 4. (currently amended): The method Use according to claim 1, wherein the
angelicin or structural analogue is in combination with at least one further modifier of the
transcription process.

Claim 5. (currently amended): The method Use according to Claim 4 in which the further modifier of the transcription process is selected from the group consisting of cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).